...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of hospital pharmacy. >Rebleeding in Variceal and Nonvariceal Gastrointestinal Bleeds in Cirrhotic Patients Using Vitamin K_1: The LIVER-K Study
【24h】

Rebleeding in Variceal and Nonvariceal Gastrointestinal Bleeds in Cirrhotic Patients Using Vitamin K_1: The LIVER-K Study

机译：使用维生素K_1在肝硬化患者中在静脉曲生和非血糖胃肠道出血中释放：肝脏-K研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Gastroesophageal varices are the most common cause of upper gastrointestinal bleeding (UGIB) in patients with cirrhosis. Vitamin K_1 is commonly administered to patients presenting with UGIB and elevated international normalized ratio, despite limited evidence to support this practice. Objectives: The primary objective was to describe the incidence of rebleeding within 30 days after vitamin K_1 administration in patients with cirrhosis and UGIB. The secondary objective was to describe prescribing patterns for vitamin K_1. Methods: This retrospective, descriptive multicentre study involved patients with cirrhosis and UGIB who were admitted to any of the 4 adult acute care hospitals in Calgary, Alberta, from January 1, 2014, to December 31, 2016. Patients were divided into 2 groups: those who received vitamin K_1 and those who did not. Results: A total of 370 patients met the inclusion criteria, of whom 243 received vitamin K_1and 127 did not. Baseline characteristics were similar between the groups. Greater proportions of patients in the vitamin K_1 group received transfusions of packed red blood cells, fresh frozen plasma, platelets, cryoprecipitate, or prothrombin concentrate during their admissions. There was no significant difference in the duration of octreotide and pantoprazole infusions. Among patients in the vitamin K_1 group, there were more admissions to the intensive care unit and longer lengths of stay. More patients in the no vitamin K_1 group had esophageal varices evident on endoscopy that required endoscopic treatment. Forty of the patients (16.5%) in the vitamin K_1 group and 7 (5-5%) in the no vitamin K_1 group had rebleeding within 30 days of the initial bleed. The median total vitamin K_1 dose administered was 25 mg. Conclusions: The study results suggest that vitamin K_1 does not reduce the incidence of rebleeding within 30 days of the initial bleed in patients with cirrhosis and UGIB.
机译：背景：胃食管静脉曲张是肝硬化患者上消化道出血（UGIB）最常见的原因。维生素K_1通常用于表现为UGIB和国际标准化比率升高的患者，尽管支持这种做法的证据有限。目的：主要目的是描述肝硬化和UGIB患者服用维生素K_1后30天内再出血的发生率。第二个目标是描述维生素K_1的处方模式。方法：这项回顾性、描述性多中心研究涉及2014年1月1日至2016年12月31日期间入住阿尔伯塔省卡尔加里市4家成人急性护理医院的肝硬化和UGIB患者。患者分为两组：服用维生素K_1的患者和未服用维生素K_1的患者。结果：共有370名患者符合纳入标准，其中243人服用维生素K_1，127人未服用。两组之间的基线特征相似。在维生素K_1组中，更多的患者在入院时接受了填充红细胞、新鲜冷冻血浆、血小板、冷沉淀或凝血酶原浓缩物的输血。奥曲肽和泮托拉唑的持续时间没有显著差异。在维生素K_1组的患者中，重症监护病房的住院人数更多，住院时间更长。在无维生素K_1组中，更多的患者在内镜下出现明显的食管静脉曲张，需要内镜治疗。维生素K_1组的40名患者（16.5%）和无维生素K_1组的7名患者（5-5%）在首次出血后30天内再次出血。维生素K_1的中位总剂量为25毫克。结论：研究结果表明，维生素K_1不能降低肝硬化和UGIB患者首次出血后30天内再出血的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号